Kymab receives £20 million Series A funding

Tuesday 13 July 2010

A novel approach to antibody development has received the backing of the global medical charity, the Wellcome Trust. Kymab Ltd of Cambridge UK has received £20 million in a Series A round to develop its technology platform.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom